Sulbactam-Durlobactam Plus Ceftriaxone Dosing and Novel Treatment Regimens for Mycobacterium abscessus Lung Disease
Sanjay Kumar Singh, Avneesh Shrivastava, Gunavanthi D. Boorgula, Mary C. Long, Brian Robbins, Pamela J. McShane, Tawanda Gumbo, Shashikant Srivastava
This study evaluates sulbactam-durlobactam plus ceftriaxone dosing and combination regimens for Mycobacterium abscessus lung disease, finding that sulbactam-durlobactam-ceftriaxone achieves the highest microbial kill in a hollow fiber model.
Antimicrobial Agents and Chemotherapy · Apr 9, 2026Peer-reviewedPharmacology & Toxicology